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ACQ- Asthma Control Questionnaire
ACT- Asthma Control Test
ATS- American Thoracic Society
ERS- European Respiratory Society
FENO- fraction of exhaled nitric oxide
ICS- inhaled corticosteroid
IQR- interquartile rangesymptoms assessed by the Asthma Control Test (ACT) at
week 24. Secondary objectives were to evaluate symptoms at
weeks 4 and 12, change in FEV1 at week 24, and the inci-
dence of severe exacerbations over the study period.
RESULTS: Twenty-nine patients (62.1% women, median age,
50.8 years) were included in the study. The median ACT score
significantly increased from 13.0 (interquartile range, 8.0-18.0)
at baseline to 21.0 (interquartile range, 14.0-24.0) at 24 weeks
(P [ .002). Only 2 of 29 patients developed at least 1 severe
exacerbation during follow-up and none of them required hos-
pitalization. Overall, 15 of 25 patients (60%) were considered as
being controlled (ACT score of ‡20 and no exacerbations) at
week 24. The percentage of patients who were receiving daily
systemic corticosteroids significantly decreased from 72.4% to
52.0% (P [ .019). Adverse events were mostly moderate and
within the range of previously reported side effects with
reslizumab.
CONCLUSION: Reslizumab is an effective and safe option for
patients with severe eosinophilic asthma and a history of
omalizumab failure.  2019 The Authors. Published by
Elsevier Inc. on behalf of the American Academy of Allergy,
Asthma & Immunology. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/). (J Allergy Clin Immunol Pract 2019;7:2277-83)
Key words: Asthma; Asthma management; Severe asthma;
Omalizumab; Reslizumab
INTRODUCTION
Asthma is a heterogeneous chronic disease of the airways that
can be stratified across several phenotypes and endotypes.1 Most
patients with asthma are well controlled by standard inhaled
therapies, but approximately 4% of the total adult asthma pop-
ulation needs additional biologic therapies because of uncon-
trolled asthma and/or recurrent exacerbations, often requiring
prolonged courses of oral corticosteroids.2 Severe asthma has a
strong impact on the patient’s health-related quality of life and
health care resource utilization.3 It has been reported that nearly
half of this population shows an eosinophilic inflammatory
pattern.4 Such patients can benefit from add-on biologic thera-
pies targeting IL-5, given the key role played by this cytokine in
inducing, maintaining, and amplifying airway eosinophilia.
Different biologic agents targeting IgE (omalizumab), IL-5, and
the IL-5 receptor (mepolizumab, reslizumab, and benralizumab)
are currently available. It is difficult to choose the optimal
treatment for a patient—with allergic and eosinophilic asthma—
who could qualify for different biologic therapies. In this clinical
scenario, some authors support the use of omalizumab as a first-line option,5 but there is a lack of information on the effec-
tiveness of other biologic agents if this drug fails to control
asthma. To our knowledge, only 1 published study addressed this
issue, and this post hoc analysis of subgroups of patients from 2
randomized controlled trials concluded that “in the atopic
phenotype of patients with severe eosinophilic asthma and a prior
history of omalizumab use, mepolizumab was effective in
reducing exacerbations and improving outcomes related to
asthma control.”6
Reslizumab is a humanized mAb of IgG4 subtype against IL-5
that has been proven to significantly reduce exacerbations in
patients with asthma inadequately controlled on at least a
medium-dose inhaled corticosteroid (ICS) and greater or equal to
400 eosinophils/mL in peripheral blood.7 The aim of this study
was to evaluate the efficacy and safety of reslizumab in patients
with severe asthma who are both allergic and eosinophilic and
have previously failed therapy with omalizumab.METHODS
We carried out a 24-week prospective, multicenter, open-label,
single-group, self-controlled study in 10 tertiary centers across
Spain. The first patient was included in April 2017, and the last
patient’s last visit was in March 2018. The main objective was to
determine whether treatment with intravenous reslizumab signifi-
cantly improved asthma symptoms assessed by the Asthma Control
Test (ACT) at week 24. Secondary objectives were to evaluate
symptoms at weeks 4 and 12, change in FEV1 at week 24, and the
incidence of severe exacerbations over the 24-week study period.
The final study protocol was approved by Galicia’s Ethics
Committee (Cod 2017/117) and the local ethics committees of the
participating centers. The study was conducted in accordance with
the latest version of the Declaration of Helsinki.
Subjects
Patients were included after written informed consent was
obtained according to the study protocol. The inclusion criteria were
as follows: (1) patients aged between 18 and 70 years; (2) who met
the European Respiratory Society/American Thoracic Society (ERS/
ATS) guidelines8 definition of severe refractory asthma; (3) with
history of omalizumab failure due to lack of effectiveness (persisting
severe exacerbations and/or uncontrolled symptoms in patients with
a poor or moderate response in the global evaluation of treatment
effectiveness scale9) after a minimum of 16 weeks of treatment and/
or adverse side effects leading to discontinuation of the drug; and (4)
blood eosinophil count of 400/mL or more at least once in the 3-year
period before visit 1 or at this initial visit. Patients were excluded if
(1) they were diagnosed with asthma-chronic obstructive pulmonary
disease overlap; (2) they had a smoking history of 10 or more pack-
years; (3) they received the last dose of omalizumab within the
preceding 5 months from the date of visit 1; (4) there was previous
exposure to another mAb; and (5) any other severe disease was likely
to interfere with the conduct of the study.
Definitions
Asthma: It is diagnosed—in accordance with the Spanish Asthma
Guidelines10—by the presence of symptoms of wheeze, breathless-
ness, or cough plus a positive bronchodilator test result (significant
improvement by >12% and 200 mL in the FEV1 10 minutes after
the inhalation of 200 mg of salbutamol) or a positive methacholine
challenge test result (a provocative concentration of methacholine of
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tional exhaled nitric oxide (FENO) levels (>50 ppb).
Severe asthma: According to the international ERS/ATS guide-
lines, this is defined as asthma that requires treatment with high-dose
ICSs plus a second controller and/or systemic corticosteroids to
prevent it from becoming “uncontrolled” or that remains uncon-
trolled despite this therapy.8
Controlled asthma: This is defined as asthma with a composite of
ACT score of more than 19, and the absence of exacerbations during
the 24-week treatment period.
Severe asthma exacerbation: It is an event characterized by a
clinically judged worsening of asthma control as evidenced by
worsening symptoms and that resulted in use of systemic cortico-
steroids and/or hospitalization.11
Study protocol
At the initial visit (visit 1), patients were started on reslizumab
3 mg/kg intravenously every 4 weeks and followed up at the
respective participating outpatient clinics at 4, 12, and 24 weeks
during the study period. At visit 1, researchers obtained and recorded
in an electronic clinical research database anthropometric data,
smoking history, atopic status assessed by skin prick testing, clinical
history and lung function data, presence of comorbidities, pharma-
cologic treatments, exacerbations, and symptoms assessed by the
validated Spanish version of the ACT12 and by the Asthma Control
Questionnaire (ACQ). Lung function, exacerbations during the
previous year, ACT score, ACQ score, adverse events, and blood
samples to measure absolute and relative eosinophil counts were also
collected at every follow-up visit.
Subjects were terminated from participation in the study if they
met 1 or more of the following criteria: (1) violation of the study
protocol during the study period, (2) lost to follow-up during the
study period, (3) consent withdrawal, and (4) intolerable side effects
of reslizumab or any severe adverse event related to the study drug.
Spirometry and bronchodilator test
Spirometry was performed at every visit by using equipment and
techniques that met standards developed by the Spanish Respiratory
Society (SEPAR).13 We have used the reference values for pulmo-
nary function testing developed by the Barcelona Collaborative
Group.14 Spirometry results included pre-/postbronchodilator FEV1
(in liters) and % predicted value, forced vital capacity (in liters and
percentage of predicted), and the ratio of FEV1 and forced vital
capacity. Bronchodilator response was defined as an increase in
postbronchodilator FEV1 of more than 12% and more than 0.2 L
(measured 15 minutes after inhalation of 200 mg of salbutamol,
using a spacer) compared with prebronchodilator FEV1.
FENO was measured by a chemiluminescence analyzer (NIOX
Mino, Aerocrine, Stockholm, Sweden) at a flow rate of 50 mL/s, in
accordance with the recommendations of the ERS/ATS task force.15
Treatment schedule
Bronchodilators, ICSs, antileukotrienes, antihistamines, nasal
corticosteroids, and comorbidity-related medication remained un-
changed during the study period, whereas the dose of systemic
corticosteroids was allowed to be adjusted according to the in-
vestigator’s judgment. Reslizumab was administered as 3 mg/kg
every 4 weeks by intravenous infusion over 20 to 50 minutes in a
health care setting by a health care professional prepared to manage
anaphylaxis.Management and treatment of asthma exacerbations were left to
the criteria of the investigators, on the basis of current standard
of care.10
Statistical methods
The sample size was calculated on the basis of the assumption that
a 3-point increase in ACT score from baseline to the final visit is a
clinically meaningful difference.16 A sample size of 24 patients
would provide a power of 80% with an a error of 0.05. Taking into
account a possible loss to follow-up of 25% and considering previous
studies,17 it was decided to enroll 30 patients.
We performed the statistical analysis of the primary and sec-
ondary end points in the intention-to-treat population, which
included all patients who received at least 1 dose of the study drug,
irrespective of possible protocol violations (eg, lost to follow-up or
discontinuation of study drug).
Continuous variables were described by medians and interquartile
ranges (IQRs), and categorical variables were described by using the
relative and absolute frequencies.
To evaluate differences in asthma outcomes between visits, cat-
egorical variables were compared using c2 analysis. On the basis of
their distributions, continuous variables were compared between
visits with Wilcoxon matched-pairs signed rank test or Student t test.
All analyses were performed using SPSS Statistics version 22 (IBM
Corporation, Armonk, NY).
RESULTS
Demographic characteristics
Twenty-nine patients were included in the study. Omalizu-
mab had been discontinued in 23 patients (79.3%) because of
the lack of effectiveness and in 6 (20.7%) because of side effects
(see Table E1 in this article’s Online Repository at www.jaci-
inpractice.org). Demographic and clinical characteristics at visit
1 are presented in Table I. Briefly, 62% were female, the median
age was 50 years, 89.6% had positive skin prick test results (this
implies that omalizumab was indicated on a compassionate, off-
label basis in 3 nonatopic subjects), and 72% were on daily
systemic corticosteroids.
Figure 1 shows the flowchart of patients through the study.
Three patients were lost to follow-up at any time during the
study and 1 was withdrawn from the study because of a serious
adverse event (toxicoderma).
Effect on asthma control
For the primary end point at 24 weeks, the median ACT score
significantly increased from 13.0 (IQR, 8.0-18.0) to 21.0 (IQR,
14.0-24.0) (P ¼ .002). The improvements from baseline were
also significant at 4 and 12 weeks: 21.0 (IQR, 13.0-24.0) and
21.0 (IQR, 15.0-24.0), respectively (P < .001) (Figure 2, A).
Sixteen of 25 patients (64%) achieved the minimal clinically
meaningful difference (at least 3 points) at the 24-week
timepoint.
The median 7-item ACQ score significantly improved from 2.4
(IQR, 1.7-3.6) at baseline to 1.4 (IQR, 0.9-2.7) at 4 weeks (P <
.001), 1.3 (IQR, 0.6-2.4) at 12 weeks (P < .001), and 1.9 (IQR,
0.9-2.6) at 24 weeks (P ¼ .004) (Figure 2, B). Thirteen of 25
patients (52%) achieved the minimal clinically meaningful dif-
ference (at least 0.5 points). The median Asthma Quality of Life
Questionnaire score significantly increased from 4.1 (IQR, 3.0-
5.1) at baseline to 5.9 (IQR, 4.2-6.3) at 4 weeks (P < .001), 6.0
(IQR, 4.5-6.5) at 12 weeks (P< .001), and 5.6 (IQR, 4.4-6.6) at
TABLE I. Characteristics of patients according to the treatment
regimen (N ¼ 29)
Variable Value*
Age (y) 50.8 (42-64)
Sex, female 18 (62.1%)
Positive skin prick test results 26 (89.6%)
IgE (IU/mL) 105 (44.9-212)
Chronic rhinosinusitis 22 (75.8%)
Polyposis 12 (41.4%)
SAHS 2 (6.4%)
ABPA 1.0 (3.4%)
GERD 7 (24.1%)
Obesity† 9 (31%)
Anxietyz 10 (34.5%)
Depressionz 6 (20.7%)
ACT score 13.0 (8.0-18.0)
ACQ-7 score 2.4 (1.7-3.6)
AQLQ score 4.1 (3.0-5.1)
FEV1 (L) 1.6 (1.3-2.3)
FEV1 (% predicted) 54.4 (42-73)
Severe exacerbations in the previous 12 mo 1.0 (0.0-2.0)
1 severe exacerbation in the previous 12 mo 17 (58.6)
Annual exacerbation rate 1.8  1.0
Corticosteroid-dependent patients 21 (72.4%)
Eosinophils (cells/mm3) at baseline 330 (200-500)
FENO (ppb) 43.0 (25.6-63.7)
ABPA, Allergic bronchopulmonary aspergillosis; ACQ-7, Asthma Control Ques-
tionnaire (7 items); AQLQ, Asthma Quality of Life Questionnaire; GERD, gastro-
esophageal reflux; SAHS, sleep apnea-hypopnea syndrome.
*Data are median (IQR) or n (%).
†Obesity is defined as body mass index score of 30 kg/m2.
zAnxiety and depression diagnoses were collected from the medical history. These
were assessed by the Hospital Anxiety and Depression Scale.
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nificant difference of 0.5 points or more in the Asthma Quality of
Life Questionnaire was observed in 16 of 25 patients (64%).
Secondary end points: Exacerbations, systemic
corticosteroids, and lung function
Only 2 of 29 patients developed at least 1 severe exacerbation
requiring initiation of systemic corticosteroids during follow-up
and none of them required hospitalization. Overall, 15 of 25
patients (60%) were considered as being controlled (composite of
ACT score of 20 and no exacerbations) at week 24.
Although the study did not include a corticosteroid-tapering
preestablished regimen, the percentage of patients who were
receiving daily corticosteroids significantly decreased from 72.4%
to 52.0% (P ¼ .019). Mean prednisone equivalent dose was 16
 14.9 mg at baseline (18 patients) and 19.0  18.2 mg at week
24 (13 patients).
The median FEV1 increased from 1.6 L (IQR, 1.3-2.3) at
baseline to 1.9 L (IQR, 1.3-2.5) at 4 weeks (P ¼ .1) and 1.8 L
(IQR, 1.2-2.7) at 24 weeks (P ¼ .1) (Figure 2, D). At the end of
the treatment period, 12 patients improved to 0.1 L or more and
8 patients to more than 0.2 L. The median total blood eosinophil
count decreased from 330 cells/mm3 (IQR, 200-500) at baseline
to 70 cells/mm3 (IQR, 20-100) at week 4 and to 70 cells/mm3
(IQR, 0-100) at week 24. The median FENO value decreased
from 43.0 ppb (IQR, 25.6-63.7) at baseline to 34.5 ppb (IQR,
23.3-59.6) at week 24.
Safety
In this study, adverse events were mostly moderate and within
the range of previously reported side effects with reslizumab. The
only severe adverse reaction to reslizumab during the study was 1
case of toxicoderma (<12 hours after the administration of the
fourth dose of the drug, the patient developed symmetrical rash
affecting predominantly her trunk and proximal limbs) that
completely resolved after stopping reslizumab and treatment with
antihistamines and systemic corticosteroids. We believe that this
adverse effect was caused by the administration of reslizumab,
because there was a clear time relation between the use of the
drug and the occurrence of the reaction, and toxicoderma dis-
appeared after medical treatment and it did not relapse after
reslizumab withdrawal. Another patient suffered a vertebral
fracture that was not deemed to be reslizumab-related. Erythema
at the site of administration was observed in 2 patients. The
various adverse events are listed in Table E2 in this article’s
Online Repository at www.jaci-inpractice.org.
DISCUSSION
This proof-of-concept pilot study shows that reslizumab can
be an effective alternative therapy for patients with severe
eosinophilic asthma who had previously failed to respond to
omalizumab. It shows that reslizumab significantly improved
symptoms and quality of life as early as week 4 and the
improvement was maintained throughout the 24 weeks of the
study. The treatment has proven to be safe, and there was only 1
serious reslizumab-related adverse event (toxicoderma) leading to
study medication withdrawal. Although the study was neither
planned nor powered to detect a reduction in exacerbations, it
must be highlighted that only 2 patients developed at least 1
severe exacerbation during the treatment period. Moreover, there
was a clinically relevant improvement in FEV1 (0.1 L) inalmost half the population. In addition, although the study was
not designed to actively taper corticosteroids to the lowest
possible dose, a remarkable proportion of patients (20%) were
able to discontinue this medication. It is quite possible that this
rate might have been improved by applying a predetermined
strategy for reducing the dose of systemic steroids, but this re-
mains to be demonstrated. It is also worth mentioning that a
high percentage of the study participants (72%) were
corticosteroid-dependent. This is not so surprising when
considering that this treatment was the only therapeutic alter-
native for patients with severe uncontrolled asthma before the
approval of biologic drugs other than omalizumab, but it should
not affect the generalizability of the results to a wider range of
patients because, to date, steroid dependence has not been
established as a predictor of response to antieIL-5 drugs.
Very few previous studies have tried to demonstrate that
patients with severe asthma who do not respond to omalizumab
can be subsequently and effectively treated with antieIL-5
therapy. A post hoc analysis of 2 clinical trials (Mepolizumab as
Adjunctive Therapy in Patients with Severe Asthma [MENSA]
and Steroid Reduction with Mepolizumab Study [SIRIUS]),18,19
which aimed to evaluate the effect of mepolizumab in patients
with severe eosinophilic asthma who had previously been treated
with omalizumab, found that the reductions in the rate of ex-
acerbations and in oral corticosteroid dose were comparable
regardless of previous omalizumab use. In addition, the 5-item
FIGURE 1. Flowchart diagram of the study.
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reduced with mepolizumab treatment compared with placebo in
both omalizumab-experienced and omalizumab-naive patients,
pointing toward an improvement in asthma control and quality
of life in patients previously treated with omalizumab. In this
respect, these results are concordant with ours.
Our study responds to a clinical need, because there are pa-
tients with severe asthma, considered as allergic, who have poor
response to omalizumab. In the present study, omalizumab had
previously been discontinued mostly because of the lack of effi-
cacy in the included patients, although the reason for discon-
tinuation was “adverse events” in 20.7% of the sample. Previous
studies report similar figures. In randomized controlled trials, the
dropout rate (an index that considers withdrawal due to lack of
efficacy and adverse events) ranges from 7.1% to 19.4%. In real-
life studies, the dropout rate ranges from 0% to 45.5%.20 In
Spain, the Spanish Severe Asthma Registry found a dropout rate
of 18.7%: 10.5% due to lack of efficacy, 5.6% on patients’ own
initiative, and 2.6% due to side effects.17 The response to
omalizumab does not seem to be related to the baseline eosin-
ophil count, because a recent study shows that a large proportion
of patients with severe allergic asthma have a blood eosinophil
count of greater than or equal to 300 cells/mL and concludes that
omalizumab effectiveness is similar in “high” and “low” eosino-
phil subgroups.21
It has been shown that 100 mg subcutaneous mepolizumab
every 4 weeks may not be effective in reducing airwayeosinophilia in some patients with severe prednisone-
dependent asthma, but higher doses of another antieIL-5
mAb (intravenous reslizumab) can control the airway eosino-
philic inflammation leading to an improvement in asthma
control.22 Our study has a similar design (the patients were
sequentially treated with 2 mAbs) but the drugs (omalizumab
and reslizumab) belong to a different pharmacological class.
Taken together, the 2 studies provide some evidence that
asthma control can be gained either by switching between 2
different antieIL-5 mAbs (when given at different doses) or by
switching between biologic drugs that target a related, but
different, inflammatory pathway.23
This study also emphasizes the effectiveness and safety of
intravenous reslizumab in patients with an allergic phenotype,
which may have potential clinical implications when deciding
the most appropriate biologic therapy for a given patient. In
severe allergic and eosinophilic asthma, both IgE and eosino-
phils are components of a complex inflammatory process in
which they have different roles. It is generally accepted that IgE
plays a fundamental role in the triggering, development, and
chronicity of the inflammatory responses in allergic asthma,
whereas eosinophils are final effector cells in this process. The
quantitative importance of each mediator is probably different
in each individual patient with asthma and the available bio-
markers are not precise enough to assess these differences. In our
population, most of the patients with asthma (89%) had a
positive skin test result and the median eosinophil count at
baseline was 330 cells/mm3. In this clinical scenario, the deci-
sion on which drug is the best choice remains difficult and
challenging for the clinicians. Because it is generally considered
that IgE is the cause of allergic airway inflammation rather than
the consequence of this process, omalizumab has been mainly
advocated to treat patients with allergy, although some positive
outcomes have also been observed in nonallergic ones.24,25
However, antieIL-5 are molecules that target the eosinophils,
effector cells located at the end stage of the adaptive and innate
immunity. Apparently, according to the results of the literature,
patients with allergy with a high blood eosinophil count would
qualify for both treatments. In this regard, in a post hoc analysis
of pooled results from 2 randomized controlled trials, benrali-
zumab has been shown to be effective for patients with severe
uncontrolled eosinophilic asthma regardless of serum IgE con-
centrations and atopy status.26 Nonetheless, no head-to-head
studies have been performed to elucidate this issue. Although
our study does not pretend to clarify this issue, it shows that at
least some of these patients, considered nonresponders to
omalizumab, will benefit from antieIL-5 mAbs.
Our study has some strengths and limitations. To our
knowledge, this is the first clinical trial specifically designed to
demonstrate that patients who fail to respond to antieIgE
therapy can be rescued with an antieIL-5 drug. Because of
the lack of a control group, a placebo effect cannot be definitely
ruled out. Nonetheless, besides the treatment with reslizumab,
little else over the course of the study could have caused the
observed improvement in the patients’ clinical condition. The
significant increase in ACT score occurred together with a
marked improvement in quality of life, asthma control, and
pulmonary function, giving consistency to the overall results.
Moreover, the local ethics committee interpreted that the use of
a placebo arm could be considered unethical in patients who are
mostly being treated with oral corticosteroids and might qualify
FIGURE 2. Changes in asthma outcomes over the study period. A, Changes in ACTscore over the 24-week study period. B, Changes in
7-item ACQ (ACQ-7) score. C, Changes in AQLQ score. D, Changes in FEV1. AQLQ, Asthma Quality of Life Questionnaire.
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2282 PÉREZ DE LLANO ETALfor an existing antieIL-5 mAb. Another limitation is the rela-
tively small population studied, but the estimated sample size
(24 patients) was reached (25 patients completed the study) and
it was powered to show statistically significant differences from
baseline. In addition, the duration of the trial was too short to
explore the effects on exacerbations. However, fewer exacerba-
tions and a positive effect on lung function were observed in
most patients.CONCLUSIONS
This is the first prospective study to demonstrate the efficacy
of using an antieIL-5 drug in a patient population with severe
allergic and eosinophilic asthma whose asthma was unresponsive
to a biologic treatment targeting the IgE pathway. Reslizumab
has been shown to be effective and safe in improving outcomes
related to asthma control (symptoms and quality of life) in pa-
tients with severe eosinophilic asthma and a history of omali-
zumab use. The results of our trial should be viewed as
hypothesis-generating and in need of testing with a long-term
randomized controlled trial to assess the clinical efficacy oftargeting the IL-5 pathway in patients with severe eosinophilic
asthma with previous omalizumab failure.Acknowledgments
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2283.e1 PÉREZ DE LLANO ETALONLINE REPOSITORYTABLE E1. Reasons for omalizumab discontinuation
Patient
Duration of omalizumab
treatment (mo)
Reason for discontinuation
Lack of efficacy
Adverse effects
No. of severe
exacerbations ACT GETE
1 6 1 17 Moderate Generalized arthromialgias
2 3 0 20 Good Generalized arthromialgias
3 11 4 18 Moderate
4 23 3 10 Poor
5 36 1 11 Moderate
6 23 8 12 Moderate
7 18 3 9 Poor
8 12 3 16 Moderate
9 6 2 17 Poor Generalized arthromialgias
10 9 6 16 Poor
11 12 4 12 Poor
12 3 1 17 Moderate Generalized arthromialgias
13 4 1 8 Poor
14 6 0 17 Moderate Generalized arthromialgias
15 6 0 15 Poor
16 24 1 9 Poor
17 32 3 12 Poor
18 9 2 8 Poor
19 36 10 12 Poor
20 8 2 20 Poor
21 12 6 5 Poor Generalized arthromialgias
22 24 0 17 Poor
23 11 3 13 Poor
24 40 1 12 Poor
25 9 0 18 Moderate Generalized arthromialgias
26 11 0 18 Poor
27 12 2 19 Moderate Generalized arthromialgias
28 9 3 12 Poor
29 15 3 16 Poor
GETE, Global evaluation of treatment effectiveness.
Note. GETE measures response to asthma treatment on a 5-point scale: excellent (complete control of asthma); good (marked improvement in asthma); moderate (discernible,
but limited improvement in asthma); poor (no appreciable change in asthma); and worsening of asthma.
TABLE E2. Adverse events
Adverse event
Cases of adverse
events
Treatment-related
adverse event
Intensity
Treatment
discontinuedMild Moderate Severe
Toxicoderma 1 1 0 0 1 1
Vertebral fracture 1 0 0 0 1 0
Nasopharyngitis 3 0 3 0 0 0
Tracheitis 1 0 1 0 0 0
Bronchitis 6 0 3 2 1 0
Influenza 4 0 4 0 0 0
Pseudomonas bronchitis 1 0 0 0 1 0
Erythema 2 2 1 1 0 0
Pruritus 2 2 2 0 0 0
Erectile dysfunction 1 0 1 0 0 0
Breast pain 1 0 1 0 0 0
Dizziness 1 0 1 0 0 0
Headache 3 0 2 0 1 0
Vertigo 1 0 1 0 0 0
Diarrhea 1 0 1 0 0 0
Nausea 1 0 1 0 0 0
Gastritis 1 0 1 0 0 0
Abdominal pain 2 0 2 0 0 0
Asthenia 4 4 2 2 0 0
Pyrexia 1 0 0 0 1 0
Arthromialgia 10 3 8 2 0 0
Arterial hypertension 3 0 3 0 0 0
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